NASHVILLE, Tenn.–(BUSINESS WIRE)—- $HROW–Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic‑focused healthcare company, today announced that it will release its financial results for the third quarter and nine months ended September 30, 2021, on Tue…
Category: Business
Global Macular Edema Market and Competitive Landscape Report 2021: Pipeline, Epidemiology, Valuations, Forecasts, Drug Sales, Drug Forecasts, and Market Shares 2018-2026 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Macular Edema Market and Competitive Landscape – 2021” report has been added to ResearchAndMarkets.com’s offering. Global Macular Edema Market and Competitive Landscape – 2021, provides comprehensive insights into M…
FDA Approves Genentech’s Susvimo, a First-of-Its-Kind Therapeutic Approach for Wet Age-Related Macular Degeneration (AMD)
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Susvimo™ (ranibizumab injection) 100 mg/mL for intravitreal…
The Worldwide Retinal Surgery Device Industry is Expected to Reach $2.7 Billion by 2027 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Retinal Surgery Device Market, Global Forecast, Impact of COVID-19, Industry Trends, by Product, Growth, Opportunity Company Analysis” report has been added to ResearchAndMarkets.com’s offering. This report provides comple…
Global Anterior Uveitis Treatment Market Growth Analysis and Insights 2021-2028 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Anterior Uveitis Treatment Market Growth Analysis and Insights, 2021: Trends, Market Size, Share Outlook and Opportunities by Type, Application, End Users, Countries and Companies to 2028” report has been added to Research…
Newly Published Data Continue to Support Long-Term Efficacy of TEPEZZA® (teprotumumab-trbw) for Thyroid Eye Disease (TED)
DUBLIN–(BUSINESS WIRE)–Horizon Therapeutics announced data supporting the long-term efficacy of TEPEZZA (teprotumumab-trbw) for the treatment of Thyroid Eye Disease (TED).
AngMar Medical Holdings, Inc. Expands Angels Care Home Health Brand With Purchase of New Provider
MANSFIELD, Texas–(BUSINESS WIRE)– #AngelsCareHH–AngMar Medical Holdings, Inc. has purchased Amarillo’s Best Home Healthcare, Inc., which will service patients out of an Amarillo, Texas, location.
Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Third-Quarter 2021 Financial Results and Discuss Recent Business Highlights
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call at 8:00 a.m. ET Thursday, October 28, 2021 to report financial results for the quarter ended September 30, 2021 and discuss recent busine…
Global Ophthalmic Drugs Market (2021 to 2029) – Featuring Abbott Healthcare, Allergan and Bayer Among Others – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Ophthalmic Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 To 2029” report has been added to ResearchAndMarkets.com’s offering…
Luminopia Announces FDA Approval of Digital Therapeutic that Uses TV Shows to Improve Vision in Children with Lazy Eye
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Luminopia Announces FDA Approval of Digital Therapeutic that Uses TV Shows to Improve Vision in Children with Lazy Eye
jCyte Announces Appointment of John Pollack, MD, FASRS, as Chief Medical Officer
NEWPORT BEACH, Calif.–(BUSINESS WIRE)–jCyte, Inc., a private biotechnology company dedicated to improving the lives of patients with retinal degenerative diseases, announced the continued expansion of the company’s executive management team with the …
Global Ophthalmic Perimeters Market (2021 to 2028) – Size, Share & Trends Analysis Report – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Ophthalmic Perimeters Market Size, Share & Trends Analysis Report By Product (Static, Kinetic, Combination), By End-use (Hospital, Ophthalmic Clinic), By Region (North America, Europe, APAC, Latin America, MEA), And Se…
Lineage to Be Featured in B. Riley Securities Fall 2021 “Growth Biotech Best Ideas” Virtual Series on October 18, 2021
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #LineageCellTherapeutics–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced t…
有關四年研究的新資料顯示，中外製藥的Enspryng可長期減少泛視神經脊髓炎 (NMOSD)患者的復發
東京–(BUSINESS WIRE)–(美國商業資訊)–中外製藥株式會社(Chugai Pharmaceutical Co., Ltd., TOKYO: 4519)公布了關於Enspryng® [學名：satralizumab（基因重組藥）]長期有效性和安全性的新資料。Enspryng是中外製藥研究生產的一種pH依賴性結合抗IL-6受體人類化單株抗體。資料顯示，Enspryng具有良好的風險/獲益特徵，在抗水通道蛋白-4抗體(AQP4-IgG)血清陽性的泛視神經脊髓炎（NMOSD，一種影響中樞…
Neue Vierjahresdaten zeigen anhaltende Rezidivreduktion durch Chugais Enspryng bei Menschen mit Neuromyelitis-optica-Spektrum-Erkrankungen (NMOSD)
TOKIO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) gab neue längerfristige Wirksamkeits- und Sicherheitsdaten für Enspryng® [generischer Name: Satralizumab (genetische Rekombination)] bekannt, einen pH-abhängig bindenden humanisierte…
De nouvelles données sur quatre ans indiquent une réduction durable des rechutes grâce à l’Enspryng de Chugai chez des patients atteints du trouble du spectre de la neuromyélite optique (NMOSD)
TOKYO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO : 4519) a annoncé de nouvelles données d’efficacité et de sécurité d’emploi à long terme concernant Enspryng® [nom générique : satralizumab (recombinaison génétique)], anticorps monoclonal …
Resumen: Nuevos datos correspondientes a cuatro años muestran una reducción sostenida de las recaídas gracias a Enspryng de Chugai en personas con trastorno del espectro de la neuromielitis óptica
TOKIO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) ha anunciado nuevos datos de eficacia y seguridad a largo plazo de Enspryng® [nombre genérico: satralizumab (recombinación genética)], un anticuerpo monoclonal humanizado contra el r…
Samenvatting: Nieuwe vierjarige gegevens tonen aanhoudende vermindering van terugval door Chugai’s Enspryng bij mensen met neuromyelitis Optica Spectrum Disorder (NMOSD)
TOKIO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) heeft nieuwe gegevens over de werkzaamheid en veiligheid op langere termijn aangekondigd voor Enspryng® [generieke naam: satralizumab (genetische recombinatie)], een pH-afhankelijke …
Riassunto: Nuovi dati quadriennali mostrano una riduzione sostenuta delle recidive nei trattamenti con Enspryng di Chugai delle persone affette da disturbo dello spettro della neuromielite ottica (NMOSD)
TOKYO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) ha reso noti nuovi dati riguardanti la sicurezza e l’efficacia a lungo termine di Enspryng® [nome generico: satralizumab (ricombinazione genetica)], un anticorpo monoclonale umanizza…
Alcon Celebrates World Sight Day 2021 in Communities Worldwide with Programs for Improved Access to Eye Care
GENEVA–(BUSINESS WIRE)–Alcon Celebrates World Sight Day 2021 in Communities Worldwide with Programs for Improved Access to Eye Care